- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02271828
Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy
Clinically Node Negative Breast Cancer Patients Undergoing Breast Conserving Therapy: Sentinel Lymph Node Procedure Versus Follow-Up.
STUDY AIM To decrease the number of breast cancer patients receiving over treatment of the axilla, in order to positively influence the axillary morbidity rate and quality of life.
PRIMARY OBJECTIVE To determine whether omitting the sentinel lymph node procedure is not inferior to the current axillary staging regimen in clinically node negative breast cancer patients undergoing breast conserving therapy, in terms of regional recurrence rate.
HYPOTHESIS The sentinel lymph node procedure can be safely omitted in clinically node negative breast cancer patients undergoing breast conserving therapy. This will lead to a decreased axillary morbidity rate, with a non-inferior regional recurrence-, distant-disease free- and overall survival rates.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marjolein L Smidt, MD, PhD
- Phone Number: +31433877477
Study Locations
-
-
-
Almere, Netherlands
- Not yet recruiting
- Flevoziekenhuis
-
Amsterdam, Netherlands
- Recruiting
- Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
-
Arnhem, Netherlands
- Recruiting
- Rijnstate
-
Breda, Netherlands
- Not yet recruiting
- Amphia Ziekenhuis
-
Den Bosch, Netherlands
- Not yet recruiting
- Jeroen Bosch Ziekenhuis
-
Den Haag, Netherlands
- Recruiting
- Haga ziekenhuis
-
Deventer, Netherlands
- Recruiting
- Deventer Ziekenhuis
-
Eindhoven, Netherlands
- Not yet recruiting
- Catharina Ziekenhuis
-
Eindhoven, Netherlands
- Recruiting
- Maxima Medisch Centrum
-
Gouda, Netherlands
- Not yet recruiting
- Groene Hart Ziekenhuis
-
Groningen, Netherlands
- Not yet recruiting
- UMC Groningen
-
Haarlem, Netherlands
- Not yet recruiting
- Spaarne Gasthuis
-
Leiden, Netherlands
- Not yet recruiting
- Alrijne
-
Nieuwegein, Netherlands
- Recruiting
- St. Antonius Ziekenhuis
-
Nijmegen, Netherlands
- Not yet recruiting
- Radboud UMC
-
Nijmegen, Netherlands
- Not yet recruiting
- Canisius-Wilhelmina Ziekenhuis
-
Roermond, Netherlands
- Recruiting
- Laurentius Ziekenhuis
-
Utrecht, Netherlands
- Not yet recruiting
- Diakonessenhuis
-
Utrecht, Netherlands
- Not yet recruiting
- UMC Utrecht
-
Woerden, Netherlands
- Recruiting
- Zuwehofpoort ziekenhuis
-
Zwolle, Netherlands
- Recruiting
- Isala Klinieken
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6202 AZ
- Recruiting
- Maastricht University Medical Centre+
-
Contact:
- Marjolein L Smidt, MD, PhD
- Phone Number: +31433877477
-
Principal Investigator:
- Marjolein L Smidt, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Aged 18 years or older
- Pathologically confirmed invasive breast carcinoma
- A clinical T1-2 tumor
- Will be treated with lumpectomy and whole breast radiotherapy
- Clinically node negative status: no signs of axillary lymph node metastases at physical examination and preoperative axillary ultrasound (or negative cyto-/histopathology)
- Written informed consent
Exclusion Criteria:
- Clinically node positive pre-operative
- Bilateral breast cancer
- Evidence of metastatic disease
- History of invasive breast cancer
- Previous treatment of the axilla with surgery or radiotherapy (except surgery for hidradenitis suppurativa or for other superficially located skin lesions, such as naevi)
- Pregnant or nursing
- Other prior malignancies within the past 5 years (except successfully treated basal cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in situ of the ipsilateral or contralateral breast) or unsuccessfully treated malignancies > 5 years before randomization
- Unable or unwilling to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sentinel lymph node procedure
Sentinel lymph node procedure according to the Dutch breast cancer guideline
|
Sentinel lymph node procedure according to the Dutch breast cancer guideline
|
No Intervention: No sentinel lymph node procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regional recurrence rate
Time Frame: Up to ten years
|
Regional recurrence is defined as tumour recurrence and as residual tumour that became clinically apparent in ipsilateral axillary, infraclavicular and supraclavicular lymph nodes (pathologically proven).
|
Up to ten years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hans JW de Wilt, MD, PhD, Radboud University Medical Centre, Nijmegen, The Netherlands
- Principal Investigator: Marjolein L Smidt, MD, PhD, Maastricht University Medical Centre, Maastricht, the Netherlands
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BOOG 2013-08 (Other Identifier: Dutch Breast Cancer Trialists' Group (BOOG))
- KWF UM 2014-6679 (Other Grant/Funding Number: The Dutch Cancer Society (KWF))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
Clinical Trials on Sentinel lymph node procedure
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female
-
The University of Hong KongActive, not recruitingBreast Cancer | Sentinel Lymph NodeHong Kong
-
Gangnam Severance HospitalCompletedNeoadjuvant Chemotherapy | Micrometastases
-
Jewish General HospitalMcGill University Health Centre/Research Institute of the McGill University...RecruitingSentinel Lymph Node | Cutaneous Squamous Cell CarcinomaCanada
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Peking University People's HospitalSun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsUnknown
-
Peking University People's HospitalSun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsUnknown
-
Centre Oscar LambretCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingConjunctival Melanoma | Porocarcinoma | Ocular Surface Squamous Neoplasia | Merkel Cell Carcinoma, Unspecified | Ocular Sebaceous Carcinoma | Ocular Basal Cell CarcinomaItaly
-
Istituto Clinico HumanitasRecruiting